Back to resultsYM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
Primary Purpose
Prostate Cancer
Status
Terminated
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
YM598
Sponsored by
About this trial
This is an interventional treatment trial for Prostate Cancer
Eligibility Criteria
Sites / Locations
- University Clinic AZ
- University Clinic UCL St. Luc
- Private Urology Out-patient Ward
- Clinic of Urology, University Hospital
- Clinic of Urology, University Hospital
- Clinic of Urology, University Hospital
- Hôpital Bichat, service de Urology
- Haingasse 22
- Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
- Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
- Krummbogen 15
- Regional Hospital, Department of Urology
- MedSource Poland
- Bielanski Hospital, Department of Urology
- Oncology Center, Department of Urinary Tract Cancer
- Medical University, Clinic of Urology
- Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
- Fundacion Hospital Alcorcón, Servicio Urología
- Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
- Department of Urology, Bristol Royal Infirmary
- Department of Urology, Gartnavel Hospital
- Department of Urology, Norfolk & Norwich Hospital
- Department of Urology, Taunton & Somerset Hospital
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00050297
First Posted
December 3, 2002
Last Updated
June 6, 2012
Sponsor
Astellas Pharma Inc
Collaborators
Astellas Pharma US, Inc.
1. Study Identification
Unique Protocol Identification Number
NCT00050297
Brief Title
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
June 2012
Overall Recruitment Status
Terminated
Study Start Date
undefined (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2004 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Astellas Pharma Inc
Collaborators
Astellas Pharma US, Inc.
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine the optimal dosage of YM598 for slowing down disease progression in patients with rising PSA after initial therapy for localized prostate cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
YM598
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Facility Information:
Facility Name
University Clinic AZ
City
Brussels
Country
Belgium
Facility Name
University Clinic UCL St. Luc
City
Brussels
Country
Belgium
Facility Name
Private Urology Out-patient Ward
City
Jablonec nad Nisou
Country
Czech Republic
Facility Name
Clinic of Urology, University Hospital
City
Králové
Country
Czech Republic
Facility Name
Clinic of Urology, University Hospital
City
Olomouc
Country
Czech Republic
Facility Name
Clinic of Urology, University Hospital
City
Prague
Country
Czech Republic
Facility Name
Hôpital Bichat, service de Urology
City
Paris
Country
France
Facility Name
Haingasse 22
City
Bad Homburg
ZIP/Postal Code
61348
Country
Germany
Facility Name
Klinik und Poliklinik für Urologie, Universitätsklinikum Carl-Gustav-Carus
City
Dresden
Country
Germany
Facility Name
Klinik u. Poliklinik für Urologie, Philipps Universität, Baldingerstraße
City
Marburg
Country
Germany
Facility Name
Krummbogen 15
City
Marburg
Country
Germany
Facility Name
Regional Hospital, Department of Urology
City
Bydgoszcz
Country
Poland
Facility Name
MedSource Poland
City
Gdansk
Country
Poland
Facility Name
Bielanski Hospital, Department of Urology
City
Warszawa
Country
Poland
Facility Name
Oncology Center, Department of Urinary Tract Cancer
City
Warszawa
Country
Poland
Facility Name
Medical University, Clinic of Urology
City
Wroclaw
Country
Poland
Facility Name
Complejo Hospitaliaro Juan Canalejo, Servicio de Urología
City
Corunna
Country
Spain
Facility Name
Fundacion Hospital Alcorcón, Servicio Urología
City
Madrid
Country
Spain
Facility Name
Hospital Universitario Principe de Asturias, Servicio de Urología, Ctra.
City
Madrid
Country
Spain
Facility Name
Department of Urology, Bristol Royal Infirmary
City
Bristol
Country
United Kingdom
Facility Name
Department of Urology, Gartnavel Hospital
City
Glasgow
Country
United Kingdom
Facility Name
Department of Urology, Norfolk & Norwich Hospital
City
Norwich
Country
United Kingdom
Facility Name
Department of Urology, Taunton & Somerset Hospital
City
Taunton
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer
We'll reach out to this number within 24 hrs